However, IBD onset is often correlated with unrestricted activation of inflammasomes, piquing the curiosity of several biotech companies which are enthusiastically performing high-throughput screening to find novel NLRP3 and pyroptosis inhibitors and improve the quality of life of affected people. The gene discussed is NLRP3; the disease is inflammatory bowel disease.